Baird raised the firm’s price target on Medpace (MEDP) to $362 from $354 and keeps a Neutral rating on the shares. The firm preiovewed its Q4 results and guidance.
Baird raised the firm’s price target on Medpace (MEDP) to $362 from $354 and keeps a Neutral rating on the shares. The firm preiovewed its Q4 results and guidance.